<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213577</url>
  </required_header>
  <id_info>
    <org_study_id>2003/112/HP</org_study_id>
    <nct_id>NCT00213577</nct_id>
  </id_info>
  <brief_title>NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder</brief_title>
  <official_title>Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus
      500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic
      urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the study has concluded normally;
  </why_stopped>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete urinary continence at baseline, and days 30, 90, 180, and 360</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of mictions or self catheterizations a day</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of leakages, urgency adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>guarding times</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urodynamics: bladder capacity, reflex volume, residual maximal capacity detrusor pressure, flow detrusor pressure</measure>
  </secondary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>type A botulinum toxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neurogenic urinary incontinence with urodynamic overactivity resistant to
             anticholinergic

        Exclusion Criteria:

          -  Pregnancy

          -  Bladder cancer

          -  Symptomatic urinary infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe GRISE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU-Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <keyword>overactive neurogenic bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

